Search results for "From Annals of Internal Medicine"


 
Results 1 - 10 of about 69 for "From Annals of Internal Medicine".
Sort by: Relevance | Newest | Oldest

Latest Beyond the Guidelines, In the Clinic target diabetes

An endocrinologist and a nephrologist discuss appropriate care for type 2 diabetes and chronic kidney disease, and the evidence supporting type 2 diabetes prevention and treatment are reviewed.
https://diabetes.acponline.org/archives/2024/06/14/6.htm
14 Jun 2024

SGLT-2 inhibitors associated with improved outcomes in stage 5 CKD patients

Patients with type 2 diabetes and stage 5 chronic kidney disease (CKD) had lower risk of progressing to dialysis or having a cardiovascular event if they took sodium-glucose cotransporter-2 (SGLT-2) inhibitors, a study found.
https://diabetes.acponline.org/archives/2024/05/10/6.htm
10 May 2024

Medicare coverage of semaglutide would be costly

Covering semaglutide for patients who are overweight and have cardiovascular disease could cost Medicare an additional $34 to $145 billion annually, researchers estimated.
https://diabetes.acponline.org/archives/2024/09/13/7.htm
13 Sep 2024

Little difference in dementia risk with SGLT-2s vs. dulaglutide

Older patients with type 2 diabetes starting sodium-glucose cotransporter-2 (SGLT-2) inhibitors had an estimated difference of less than a percentage point in five-year risk of clinical onset of dementia compared with those starting the glucagon-like peptide-1 receptor agonist dulaglutide, a South Korean study found.
https://diabetes.acponline.org/archives/2024/09/13/6.htm
13 Sep 2024

Case report of DKA from a gout flare

A recently published case described a patient with a history of tophaceous gout who developed diabetic ketoacidosis (DKA) during a severe acute polyarticular gout flare.
https://diabetes.acponline.org/archives/2024/09/13/9.htm
13 Sep 2024

Use of GLP-1 receptor agonists rose steeply in past decade, study finds

A million U.S. patients, mostly women, started taking glucagon-like peptide-1 (GLP-1) receptor agonists between 2011 and 2023, according to an analysis of medical records across the country.
https://diabetes.acponline.org/archives/2024/08/09/6.htm
9 Aug 2024

California's insulin plan, clinical decision support in lower-income countries

Recent articles from Annals of Internal Medicine discussed California's plan to produce insulin and a diabetes clinical decision support system that may be helpful in primary care in low- to middle-income countries.
https://diabetes.acponline.org/archives/2022/12/09/8.htm
9 Dec 2022

Case report of insulin autoimmune syndrome

A recently published case described a patient with type 2 diabetes treated with metformin who had recurrent spontaneous hypoglycemia.
https://diabetes.acponline.org/archives/2024/07/12/8.htm
12 Jul 2024

Two case reports describe complications in patients with diabetes

One case report described a type 1 diabetes patient with disseminated mucormycosis with rhinocerebral and pulmonary involvement, while the other reported a case of euglycemic diabetic ketoacidosis related to semaglutide.
https://diabetes.acponline.org/archives/2024/06/14/10.htm
14 Jun 2024

Diabetes increases largely explained by BMI growth, especially in women

Since the late 1970s, diabetes prevalence has increased significantly more in men than women, and only in women did changes in body mass index (BMI) fully explain the diabetes trend.
https://diabetes.acponline.org/archives/2014/09/12/4.htm
12 Sep 2014

Result Page: Prev   1   2   3   4   5   6   7   Next